1. Newsroom
  2. Swiss Equities – Structural value creation
Menu
Insight 13.07.2020

Swiss Equities – Structural value creation

Swiss Equities  – Structural value creation

The resilience of the Swiss economy has once again been proved during the COVID-19 pandemic and is reflected by the Swiss equity market’s year-to-date outperformance.


Key points:

  • Several Swiss companies across all market cap segments have benefited from the disruption caused by the pandemic, as they have exposure to structural long-term trends which were accelerated by the crisis.
  • However, the strongest argument for a Swiss equity allocation within a diversified equity portfolio remains the long-term structural outperformance of Swiss equities driven by their superior value creation and ESG profiles.
  • An active investment approach driven by fundamentals and supported by extensive expertise and knowledge of the market, has led to an impressive track record and substantial AUM growth for UBP’s Swiss equity franchise over the last fourteen years.

Switzerland and COVID-19

In early June 2020, the Deep Knowledge Group, a consortium of companies and non-profit organisations, issued an update on their COVID-19 Regional Safety Assessment report, which uses a host of data points to rank the COVID-19 safety and risk assessments of 200 countries. Switzerland received the highest overall score for the effective measures it put in place to stop the spread of the virus, combined with the underlying quality of the nation’s medical system and the resilience of the country’s economy.

As in previous crises, the safe-haven status of the Swiss franc and an inflation rate of only 0.2% (as at the end of 2019) have contributed to weathering this storm in the past few months. Switzerland has an independent central bank which operates free of political pressure. The Swiss National Bank has been working with negative interest rates since 2015 and has intervened in foreign exchange markets when necessary to absorb external shocks and ease upside pressure on the Swiss franc.

Switzerland’s fiscal stability has allowed the country’s parliament to swiftly provide a substantial aid package of CHF 57 billion to support the domestic economy. In addition, the Swiss loan programme, which was developed through close collaboration between the government and Swiss banks to offer SMEs quick and simple access to loans to cover their immediate liquidity needs, has won international acclaim.

Over the first few volatile months of 2020, the Swiss equity market reflected the solid standing of the country and its companies, outperforming most major global equity markets by limiting downside while at the same time participating in strong upward moves.

The SPI Extra, the Swiss small- and mid-cap index, has shown similar resilience compared with major global and regional indices, both year-to-date and over the longer term.

The 2020 EPS growth estimate for global equities dropped further to -17% over the course of May compared with -10% at the end of April, while the 2021 estimate now stands at +26%. Expected earnings growth rates by region for 2020 range from +2% for China to -26% for the eurozone and -23% for the US; for Switzerland analysts expect a comparatively benign decline in EPS of -8%.

Swiss companies are innovation leaders in various industries, probably most visibly in medical technologies. Close to 700 Swiss companies specialise in this field, ranging from big players, such as Novartis, Roche and Lonza, to listed small- and mid-sized companies, such as Tecan, Vifor Pharma and Straumann, to a host of privately-owned companies.

The healthcare sector in Switzerland has been a strong performer year-to-date, boosted by positive news on companies, such as Lonza and Roche, both of whom are potential beneficiaries of developments in the COVID-19 situation. Lonza (up 34% year-to-date) is the best contributor to the SPI’s performance over 2020. While the company has suffered minor supply disruptions linked to COVID-19, a deal with Moderna to become their manufacturing partner in the development of a COVID-19 vaccine has driven the share price in the short term. In the long term, Lonza will remain a key beneficiary of the structural trend towards more outsourcing in the pharmaceutical industry.

 

In the small- and mid-cap segment, the IT company Logitech and medical lab supplier Tecan have been the strongest contributors to the SPI Extra’s year-to-date performance. Apart from these names, several other beneficiaries of positive newsflow can be found in the Swiss market across both sectors and market caps.

Structural, long-term value creation

Despite its small size in terms of geography, Switzerland ranks fifth in the MSCI AC World, with a 3% weighting and a total market capitalisation over CHF 1.3 trillion as at May 2020. Swiss equities offer a lower correlation to global equities and are supported by a strong underlying currency, which can benefit investors who seek real returns. Most sectors and companies have adapted to the currency’s strength; for instance, the pharmaceutical industry, which accounts for a significant share of exports, boosts high pricing power, as it is less affected by short-term economic fluctuations. Some small- and mid-cap names are indispensable to their large global customers and have cemented leading market positions in their respective industries.

As mentioned previously, Swiss equities, especially in the small- and mid-cap segment, tend to outperform global equities over both short and longer periods of time. Contrasting these superior relative returns with the relative volatility incurred underlines the attractiveness of Swiss equities even more, as they deliver one of the highest risk-adjusted returns among major equity markets.

This structural outperformance is linked to the high level of value creation, as measured by the spread of the cash flow return on investment (CFROI) over the cost of capital in the Swiss & Global Equity team’s investment framework. Switzerland has historically, and until recently, delivered consistently high CFROI spreads compared with other regional markets. It is worth noting that the quality and value creation potential of the small- and mid-cap segment has been improving over recent years, which was reflected by its strong outperformance over the period.

As passive investment options in Swiss equities are somewhat limited and concentrated on large caps, an active investment approach is the best way to gain exposure to the substantial value-creation potential of the small- and mid-cap segment. As the segment is much less covered by sell-side analysts than the companies in the SMI, there are also ample alpha opportunities that can be exploited by active managers with the experience and expertise of UBP’s Swiss equity franchise.

As at June 2020, UBP’s range of active Swiss equity strategies (UCITS and Swiss contractual fund structures) built on the CFROI life-cycle framework, has a track record of fourteen years for the flagship Swiss Equity strategy, and five years for the Swiss Small- and Mid-Cap strategy (since 30 June 2006 and 30 June 2015 respectively). Both strategies show sustainable, superior value-creation profiles compared with their respective benchmarks, as well as superior ESG profiles, with AA ratings for both, and an MSCI ESG quality score above 7.5.

The historical sector breakdown of the strategies shows a consistent and balanced allocation to sectors over time, while stock selection has always been the main driver of performance for both funds. A fundamental bottom-up investment process is key to delivering superior value creation over both the short and long term. UBP’s Swiss equity strategies remain well positioned for short-term momentum, as well as long-term structural drivers, without the need to time markets or themes.

Read the full document with charts

TAYLOR JOLIDON Eleanor.jpg

Eleanor Taylor Jolidon
Co-Head of Swiss & Global Equity

Kesrewani_Ariane_150x150.jpg

Ariane Kesrewani
Investment Specialist

Expertise

Swiss & Global Equities

Why Swiss equities now? This market offers equity investors the stability and agility they need to navigate this volatile period. 

Read more
Expertise

European Equities

European equities offer unrivalled opportunities in terms of breadth of sector and market exposure.

Read more

Most read

Insight 01.10.2020

COVID-19: UBP keeps you up to date

Since this coronavirus appeared, UBP has provided its clients with guidance and support as we all tackle this unprecedented global health crisis. We give you regular updates on everything from our own safety protocols and the recommendations issued by the authorities to our experts’ latest analysis on the effects of the pandemic on the world economy and financial markets.

Insight 30.06.2020

UBP Investment Outlook 2020 Reset

The Global Economy at the Crossroads

Insight 24.06.2020

Market turmoil brings new opportunities for pragmatic investors

March 2020 was difficult time for many investors, as COVID-19 spread across Europe and the US, leading to sharp sell-offs in fixed-income credit markets. While such market turbulence is not to be welcomed, its occurrence can create opportunities.


Further reading

Insight 02.12.2020

Swiss Small and Mid-Cap Equities – Consistent value creation

The Swiss economy has once again proven its resilience during the Covid-19 pandemic, as reflected by year-to-date outperformance in the Swiss equity market and also its small and mid-cap segment. 

Insight 24.11.2020

Hidden gems in Swiss & European small caps

Small and mid caps have traditionally recorded higher growth rates and investment returns over the long term than large caps: it is easier to generate a dynamic growth rate from a smaller base. Swiss and European small and medium-sized capitalisations – so-called ‘SMID caps’ – also tend to provide investors with ‘pure play’ exposure to major secular growth trends.

Insight 21.11.2020

UBP Investment Outlook 2021

A Brave New World